About Dyadic International, Inc.
https://www.dyadic.comDyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States.
CEO
Mark A. Emalfarb
Compensation Summary
(Year 2024)
Total Compensation $1,039,797
Industry Biotechnology
Sector Healthcare
Went public January 16, 2008
Method of going public IPO
Full time employees 6
ETFs Holding This Stock
Summary
Total 12
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Discounted Cash Flow 1
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Price Target
Target High $3
Target Low $3
Target Median $3
Target Consensus $3
Institutional Ownership
APIS CAPITAL ADVISORS, LLC
Shares:1.54M
Value:$1.35M
CHAPIN DAVIS, INC.
Shares:932K
Value:$819.79K
VANGUARD GROUP INC
Shares:914.96K
Value:$804.8K
Summary
% Of Shares Owned 17.31%
Total Number Of Holders 47
Showing Top 3 of 47
Market Cap $35.02 M
52w High $1.79
52w Low $0.71
P/E -4
Volume 51.99K
Outstanding Shares 36.17M
About Dyadic International, Inc.
https://www.dyadic.comDyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.16M ▲ | $2.84M ▲ | $-1.98M ▼ | -169.67% ▲ | $-0.06 ▼ | $-1.89M ▼ |
| Q2-2025 | $463.45K ▲ | $1.58M ▼ | $-1.79M ▲ | -387.05% ▲ | $-0.06 ▲ | $-1.68M ▲ |
| Q1-2025 | $183.1K ▼ | $1.89M ▼ | $-2.03M ▼ | -1.11K% ▼ | $-0.07 ▼ | $-1.91M ▼ |
| Q4-2024 | $817.38K ▼ | $1.99M ▲ | $-1.55M ▼ | -189.74% ▼ | $-0.05 ▼ | $-1.42M ▼ |
| Q3-2024 | $1.96M | $1.76M | $-203.46K | -10.39% | $-0.01 | $-75.29K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $10.25M ▲ | $11.67M ▲ | $9.07M ▲ | $2.61M ▲ |
| Q2-2025 | $4.98M ▼ | $8.14M ▲ | $8.67M ▲ | $-529.7K ▼ |
| Q1-2025 | $7.35M ▼ | $7.89M ▼ | $6.97M ▼ | $923.61K ▼ |
| Q4-2024 | $9.26M ▼ | $9.93M ▼ | $7.46M ▲ | $2.47M ▼ |
| Q3-2024 | $9.92M | $10.81M | $7.39M | $3.41M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.98M ▼ | $-1.85M ▼ | $93.44K ▲ | $4.94M ▲ | $3.43M ▲ | $-1.85M ▼ |
| Q2-2025 | $-1.79M ▲ | $-130.01K ▲ | $-961.62K ▼ | $0 ▼ | $-1.09M ▲ | $-130.01K ▲ |
| Q1-2025 | $-2.03M ▼ | $-1.95M ▼ | $482.1K ▼ | $24.25K ▼ | $-1.44M ▼ | $-1.95M ▼ |
| Q4-2024 | $-1.55M ▼ | $-696.39K ▼ | $1.26M ▲ | $24.25K ▲ | $585.14K ▲ | $-696.39K ▼ |
| Q3-2024 | $-203.46K | $-201.06K | $-11.98K | $0 | $-211.78K | $-201.06K |
Revenue by Products
| Product | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 Grant | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 License | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Research and Development | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Mark A. Emalfarb
Compensation Summary
(Year 2024)
Total Compensation $1,039,797
Industry Biotechnology
Sector Healthcare
Went public January 16, 2008
Method of going public IPO
Full time employees 6
ETFs Holding This Stock
Summary
Total 12
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Discounted Cash Flow 1
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Price Target
Target High $3
Target Low $3
Target Median $3
Target Consensus $3
Institutional Ownership
APIS CAPITAL ADVISORS, LLC
Shares:1.54M
Value:$1.35M
CHAPIN DAVIS, INC.
Shares:932K
Value:$819.79K
VANGUARD GROUP INC
Shares:914.96K
Value:$804.8K
Summary
% Of Shares Owned 17.31%
Total Number Of Holders 47
Showing Top 3 of 47